Lynch Syndrome
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Lynch Syndrome
Lynch syndrome is an inherited condition that increases the risk of colorectal and endometrial cancers. Protheragen offers comprehensive solutions to researchers and pharmaceutical companies who seek to develop new therapies for Lynch syndrome. Start a new path in Lynch syndrome research with our services.
Lynch syndrome is characterized by high lifetime risks of specific cancers, including colorectal and endometrial cancers. Even more concerning is the development of microsatellite instability (MSI) associated with the cellular level due to aberrant mismatch repair mechanisms. People with Lynch syndrome have a lifetime colorectal cancer (CRC) risk between 10% to 80%, with specific MMR mutation types and age being significant factors. Lynch syndrome is estimated to represent 3-5% of all colorectal cancers.
Fig.1 The human DNA mismatch repair system. (Abildgaard, A. B., et al., 2023)Lynch syndrome is caused by germline pathogenic variants in one or more of the four DNA mismatch repair genes or deletions of EPCAM. Lynch syndrome is a genetic cancer syndrome that affects the individual in an autosomal dominant fashion. The lifetime cancer risk for individuals with mutations in MLH1 and MSH2 is considerably elevated and accounts for 70-90 percent of the cases of Lynch syndrome. Even a smaller proportion (1-3%) of these instances may be due to constitutional epimutations within MLH1 or MSH2.
| Drug Names | Mechanism of Action | Targets | Research Phase |
| Pembrolizumab | Operates by obstructing the PD-1 receptors on T-cells, hence stifling cancer cells to escape the immune response. | PD1 | Phase III |
| FSP vaccination | FSP-specific adaptive immunity greatly increased, intestinal tumor burden decreased, and overall survival was prolonged. | FSP | Phase I/II |
| Naproxen | Activated different resident immune cell types and decreased the concentration of prostaglandin E2 in the colorectal mucosa. | / | Phase I |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
It gives us great honor to present to you our research services firm which specializes in Lynch syndrome disease research and therapeutic development. Our veterans and seasoned experts have a profound breadth of knowledge and expertise making us a singularly inclusive firm. As such, we provide one-stop solutions including diagnostic, therapeutic, and disease model development services.
Moreover, the development of precise and dependable animal models for Lynch syndrome is crucial for preclinical drug screening because it enables researchers to identify viable drug candidates, tailor dosing strategies, and estimate adverse effects before human trials. We offer services in custom animal model development which are key in the drug development process for Lynch syndrome.
Genetically altered animal model designed to bear mutations in key mismatch repair genes linked to Lynch syndrome.
Implantation of patient-derived colorectal cancer tissue harboring Lynch syndrome mutations into immunodeficient animals to create models that closely mimic the genetic characteristics of the original tumor.
Recognizing the specific challenges associated with Lynch syndrome studies, Protheragen provides customized pharmacokinetic studies, biosafety analysis services, and much more. Our specialists will assist you in the study of Lynch syndrome starting from genotyping to preclinical studies, and more. Together let us take a step towards the fight against Lynch syndrome. For questions about any of the services, we can be reached at any time.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.